Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lignocaine for sedation support during GI endoscopy
ACTRN12616001648415Phase 4Withdrawn
- Sponsor
- Daniel Ellyard
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lidocaine in gastrointestinal conditions, sponsored by Daniel Ellyard. Primary endpoint: Midazolam dose required. Planned start Jul 2017; status: withdrawn.
02
Drugs
lidocaine
03
Conditions
gastrointestinal conditions
Beyond the preview
Go deeper on ACTRN12616001648415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001648415.